Arian Pano - 10 Jun 2021 Form 3 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role
Chief Clinical Dev. Officer
Signature
/s/ Arian Pano
Issuer symbol
KNSA
Transactions as of
10 Jun 2021
Net transactions value
$0
Form type
3
Filing time
21 Jun 2021, 17:37:37 UTC
Next filing
07 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding KNSA Class A Common Shares 1,539 10 Jun 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding KNSA Share Option 10 Jun 2021 Class A Common Shares 100,000 $10.14 Direct F1
holding KNSA Share Option 10 Jun 2021 Class A Common Shares 30,000 $15.52 Direct F2
holding KNSA Share Option 10 Jun 2021 Class A Common Shares 30,000 $15.50 Direct F3
holding KNSA Share Option 10 Jun 2021 Class A Common Shares 23,325 $22.89 Direct F4
holding KNSA Restricted Share Units 10 Jun 2021 Class A Common Shares 3,888 Direct F5, F6
holding KNSA Restricted Share Units 10 Jun 2021 Class A Common Shares 4,867 Direct F6, F7
holding KNSA Restricted Share Units 10 Jun 2021 Class A Common Shares 3,240 Direct F6, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vested and became exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is November 11, 2019.
F2 The option vested and became exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is March 13, 2020.
F3 The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is September 10, 2020.
F4 The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is March 16, 2021.
F5 The Restricted Share Units (RSUs) vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021.
F6 Each RSU represents a contingent right to receive one Class A Common Share of the Issuer.
F7 The performance criteria for these RSUs were met. The RSUs will vest in a single installment on March 20, 2022, subject to the Reporting Person's continuous employment with the Issuer or any of its subsidiaries on the vesting date; there is no expiration date for the RSUs.
F8 The performance criteria for these RSUs were met. The RSUs will vest in a single installment on March 20, 2023, subject to the Reporting Person's continuous employment with the Issuer or any of its subsidiaries on the vesting date; there is no expiration date for the RSUs.

Remarks:

Exhibit 24 - Power of Attorney.